Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.95 USD
Change Today +0.045 / 0.27%
Volume 711.8K
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$16.78
Previous Close
$16.90
Day High
$17.06
Day Low
$16.01
52 Week High
07/3/14 - $31.80
52 Week Low
02/2/15 - $10.58
Market Cap
2.0B
Average Volume 10 Days
480.9K
EPS TTM
$-0.60
Shares Outstanding
116.9M
EX-Date
06/10/15
P/E TM
--
Dividend
$1.00
Dividend Yield
4.43%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

12 Employees
Last Reported Date: 05/8/15
Founded in 1996

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $557.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $87.8K
Senior Vice President of Corporate Partnershi...
Total Annual Compensation: $219.2K
Senior Vice President of Corporate Partnershi...
Total Annual Compensation: $192.9K
Compensation as of Fiscal Year 2014.

theravance inc (THRX) Key Developments

Theravance Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:00 PM

Theravance Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 01:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Michael W. Aguiar, Chief Executive Officer, President and Director.

Theravance Inc. Declares Cash Dividend, Payable on June 30, 2015; Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Theravance Inc. announced that the company's board of directors has declared a $0.25 per share cash dividend to be paid on June 30, 2015 to stockholders of record as of the close of business on June 12, 2015. The company announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $6,896,000 compared to negative of $780,000 a year ago. Income from operations was $754,000 compared to loss from operations of $14,723,000 a year ago. Loss from continuing operations, net of tax was $10,667,000 or $0.09 per basic and diluted share compared to $16,182,000 or $0.15 per basic and diluted share a year ago. Net loss was $10,667,000 or $0.09 per basic and diluted share compared to $67,703,000 or $0.62 per basic and diluted share a year ago. Adjusted EBITDA was $6,161,000 compared to loss of $6,885,000 a year ago.

Theravance Gets FDA Approval for Breo Ellipta for 18 Year Olds

Theravance Inc. said that FDA approved BREO ELLIPTA for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm. The FDA issued a complete response letter related to the proposed use of Breo Ellipta in patients aged 12-17 stating that the data submitted do not show adequate risk-benefit to support the approval in these patients. The FDA stated that additional data would be required to further demonstrate the safety and efficacy in this population.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $16.95 USD +0.045

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $13.64 USD -0.47
Nektar Therapeutics $11.48 USD -0.02
Progenics Pharmaceuticals Inc $5.59 USD -0.04
Sucampo Pharmaceuticals Inc $17.02 USD +0.79
Synergy Health PLC 1,834 GBp +21.00
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.thrxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.